Aditxt Inc. (ADTX)vsJohnson & Johnson (JNJ)
ADTX
Aditxt Inc.
$0.00
-6.82%
HEALTHCARE · Cap: $9.48M
JNJ
Johnson & Johnson
$256.98
-0.82%
HEALTHCARE · Cap: $623.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 671980346% more annual revenue ($96.36B vs $14,340). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ADTX
Avoid33
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADTX.
Margin of Safety
-88.3%
Fair Value
$136.51
Current Price
$256.98
$120.47 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1094.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
The strongest argument for ADTX centers on Revenue Growth, Debt/Equity. Revenue growth of 1094.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ADTX profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
ADTX is growing revenue faster at 1094.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 33/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?